If You'd Invested $100 in Viking Therapeutics Stock 2 Years Ago, Here's How Much You'd Have Today
Viking Therapeutics (NASDAQ: VKTX) stock is soaring. Two years ago, the share price hovered just above $2. Today, shares trade around $62. At Friday's prices, a paltry $100 investment in 2022 would have grown to more than $2,700!
Is there still time for you to take advantage? Absolutely.
Viking Therapeutics stock may keep soaring
Viking develops therapies to treat obesity. Two of its drug candidates -- VK2809 and VK2735 -- are currently in phase 2 trials, with promising early results. Patients using VK2735, for example, experienced a mean body weight reduction of up to 15% in just 13 weeks.
Viking is achieving drug pipeline success at the right time. The global market for weight loss drugs is just beginning to take off. Goldman Sachs sees the anti-obesity drug market reaching $100 billion by 2030. "The chronic weight management market is undergoing an inflection," explains one of the firm's analysts, "with potential for solid growth ahead and a peak opportunity that, by our estimates, could ultimately yield some of the highest grossing drugs of all time."
There will be plenty of competition. Roche's CT-388 candidate, for example, recently showed an average weight loss of 19% in a small phase 1 trial. But with a market cap of just $7 billion, plus a few more early stage drug candidates, Viking would only need to capture a small segment of its target market in the coming years to justify its valuation. With $963 million in available capital, it should have no problem getting its drugs to market should phase 3 trials complete successfully.
Don't be surprised to see shares exhibit extreme volatility from here. Viking's drug pipeline, while promising, is still years out from being commercialized. And results from competing drugs could dramatically affect the share price at any moment. But if you want to bet on the long-term wave of anti-obesity drugs, Viking remains a great pick for patient investors.
Should you invest $1,000 in Viking Therapeutics right now?
Before you buy stock in Viking Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $652,342!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of May 13, 2024
Ryan Vanzo has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Goldman Sachs Group. The Motley Fool recommends Roche Ag. The Motley Fool has a disclosure policy.
